子宮內膜癌市場規模、佔有率、成長分析、按癌症類型、按治療方法、按診斷方法、按階段、按最終用途、按地區 - 行業預測，2025 年至 2032 年

預計 2023 年全球子宮內膜癌市場規模將達到 286.9 億美元，將從 2024 年的 301.0 億美元成長到 2032 年的 441.3 億美元，預測期內（2025-2032 年）的複合年成長率為 4.9%。

隨著發病率上升、認知度提高和醫療保健基礎設施加強，全球子宮內膜癌市場正在經歷強勁成長。分子分析和基因檢測等診斷工具的創新正在帶來更精確和個人化的治療方案。隨著標靶治療、免疫療法和聯合治療的出現以及治療效果的改善，市場正在進一步擴大。基因組分析和液態切片等進步有助於更早發現和發展個人化治療方法。然而，治療費用高、獲得先進醫療服務的機會有限以及迫切需要有效的早期檢測方法等挑戰仍然是解決子宮內膜癌全球影響的重大障礙。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

子宮內膜癌市場規模（依癌症類型）

• 市場概況
• 子宮內膜癌
  • 腺癌
  • 癌症肉瘤
  • 鱗狀細胞癌
  • 其他類型癌症
• 子宮肉瘤

子宮內膜癌市場規模（依治療方法）

• 市場概況
• 外科手術
• 化療
• 放射治療
• 荷爾蒙療法
• 標靶治療
• 免疫療法

子宮內膜癌市場規模（依診斷方法）

• 市場概況
• 切片檢查
• 超音波
• 子宮鏡檢查
• 電腦斷層掃描
• 其他診斷方法

子宮內膜癌市場規模（按階段）

• 市場概況
• 第一階段
• 第二階段
• 第三階段
• 第四階段

子宮內膜癌市場規模（依最終用途分類）

• 市場概況
• 醫院
• 癌症中心
• 門診手術中心

子宮內膜癌市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• GlaxoSmithKline plc（GSK）（United Kingdom）
• Merck & Co., Inc.（United States）
• Notable Product：Keytruda（pembrolizumab）
• AstraZeneca plc（United Kingdom）
• Notable Product：Imfinzi（durvalumab）
• Novartis AG（Switzerland）
• Pfizer Inc.（United States）
• F. Hoffmann-La Roche AG（Switzerland）
• Bristol Myers Squibb Company（United States）
• Karyopharm Therapeutics Inc.（United States）
• Siemens Healthineers AG（Germany）
• Takeda Pharmaceutical Company Limited（Japan）
• Incyte Corporation（United States）
• Context Therapeutics Inc.（United States）
• Evergreen Therapeutics, Inc.（United States）
• Sysmex Corporation（Japan）
• Gilead Sciences, Inc.（United States）
• Johnson & Johnson（United States）
• AbbVie Inc.（United States）
• Sanofi SA（France）

結論和建議

Global Endometrial Cancer Market size was valued at USD 28.69 billion in 2023 and is poised to grow from USD 30.1 billion in 2024 to USD 44.13 billion by 2032, growing at a CAGR of 4.9% during the forecast period (2025-2032).

The global endometrial cancer market is experiencing robust growth, fueled by rising incidence rates, heightened awareness, and enhanced healthcare infrastructure. Innovations in diagnostic tools, including molecular profiling and genetic testing, are leading to more precise and personalized treatment options. The market is further expanding due to the emergence of targeted therapies, immunotherapies, and combination treatment modalities that provide improved outcomes. Advancements such as genomic profiling and liquid biopsies facilitate early detection and tailored treatment approaches. Nevertheless, challenges like high treatment costs, limited access to advanced healthcare services, and the pressing need for effective early detection methods continue to pose significant hurdles in addressing the global impact of endometrial cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Endometrial Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Endometrial Cancer Market Segmental Analysis

Global Endometrial Cancer Market is segmented by Cancer Type, Treatment, Diagnosis Method, Stage, End Use and region. Based on Cancer Type, the market is segmented into Endometrial carcinoma and Uterine sarcoma. Based on Treatment, the market is segmented into Surgery, Chemotherapy, Radiation therapy, Hormone therapy, Targeted therapy and Immunotherapy. Based on Diagnosis Method, the market is segmented into Biopsy, Pelvic Ultrasound, Hysteroscopy, CT Scan and Other Diagnosis Methods. Based on Stage, the market is segmented into Stage I, Stage II, Stage III and Stage IV. Based on End Use, the market is segmented into Hospitals, Cancer centers and Ambulatory surgical centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Endometrial Cancer Market

The global endometrial cancer market is significantly driven by the rising incidence of this prevalent gynecological cancer. Factors such as obesity, hormonal imbalances, and diabetes are contributing to a steady increase in cases, prompting a growing need for effective diagnostic and therapeutic options. This heightened demand for solutions not only accelerates market growth but also emphasizes the importance of advancements in medical technology and enhanced screening methods. These innovations facilitate early detection and treatment of endometrial cancer, ultimately leading to improved patient outcomes and further stimulating investments in healthcare infrastructure to combat this escalating health concern.

Restraints in the Global Endometrial Cancer Market

One significant challenge facing the global endometrial cancer market is the combination of high treatment costs and restricted healthcare accessibility, particularly in developing countries. The financial burden associated with treatment options like surgeries, chemotherapy, and radiation therapy can be overwhelming for many patients, especially those lacking sufficient health insurance or financial resources. Furthermore, in various regions, inadequate healthcare infrastructure, including a shortage of diagnostic services and specialized professionals, complicates the timely and effective treatment of endometrial cancer. To enhance patient outcomes worldwide, it is essential to tackle these obstacles by improving both the affordability and accessibility of quality healthcare.

Market Trends of the Global Endometrial Cancer Market

The Global Endometrial Cancer market is experiencing a notable trend of increased collaborations and partnerships among pharmaceutical companies and research institutions, aimed at expediting drug development and clinical trials. This strategic synergy enhances the focus on innovative diagnostics and the introduction of novel therapeutic options, ultimately translating into improved patient outcomes. Moreover, the rising incidence of endometrial cancer and heightened awareness surrounding women's health are driving the demand for advanced treatment solutions. As stakeholders prioritize research investments and regulatory approvals, this collaborative landscape is likely to foster a dynamic market, positioning it for accelerated growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Endometrial Cancer Market Size by Cancer Type & CAGR (2025-2032)

• Market Overview
• Endometrial carcinoma
  • Adenocarcinoma
  • Carcinosarcoma
  • Squamous Cell Carcinoma
  • Other Types of Cancer
• Uterine sarcoma

Global Endometrial Cancer Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Surgery
• Chemotherapy
• Radiation therapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

Global Endometrial Cancer Market Size by Diagnosis Method & CAGR (2025-2032)

• Market Overview
• Biopsy
• Pelvic Ultrasound
• Hysteroscopy
• CT Scan
• Other Diagnosis Methods

Global Endometrial Cancer Market Size by Stage & CAGR (2025-2032)

• Market Overview
• Stage I
• Stage II
• Stage III
• Stage IV

Global Endometrial Cancer Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Hospitals
• Cancer centers
• Ambulatory surgical centers

Global Endometrial Cancer Market Size & CAGR (2025-2032)

• North America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • US
  • Canada
• Europe (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Cancer Type, Treatment, Diagnosis Method, Stage, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• GlaxoSmithKline plc (GSK) (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Keytruda (pembrolizumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Notable Product: Imfinzi (durvalumab)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Karyopharm Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incyte Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Context Therapeutics Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evergreen Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations